Margo Roberts

Margo Roberts, PhD, is former CSO of Kite Pharma (acquired by Gilead in 2017) and Lyell Immunopharma. At Kite, she built a talented research organization that played an instrumental role in the successful development of Yescarta®, and the clinical advancement of additional CAR/TCR-engineered T-cell therapies. Dr. Roberts has almost three decades of biomedical research experience in both biotechnology and academia and is the inventor on thirteen issued US patents and three published US patent applications related to CAR technology and tumor vaccine therapies. She completed her PhD and undergraduate studies at the University of Leeds in England.